ABCB1 and adrenal cortex carcinoma: Thus, inhibition of DLK1 could be a strategy to reduce resistance to chemotherapy in ACC, particularly the EDP (etoposide, doxorubicin, cisplatin) regimen, which includes two chemotherapeutic drugs known to be ABCB1 transport substrates (etoposide and doxorubicin).